A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.
Dr. John Cush RheumNow
3 years 5 months ago
FDA approves a NGF inhbitor bedinvetmab (Librela) to treat osteoarthritis in Dogs!. Recently FDA approved NGF inhibitor cats w/ OA --- Yet 4 different NGF inhibitors failed in their development for human OA - are cats & dogs treated better than us? https://t.co/Tbca0PiEL2 https://t.co/Y7mViSa5J4
Dr. John Cush RheumNow
3 years 5 months ago
One in Ten is Bad!
This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!
https://t.co/5SXPotfhs0 https://t.co/jXwsWoltsy
Dr. John Cush RheumNow
3 years 5 months ago
RheumThoughts: Giving Good Care in Diversity takes Time
Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes.
https://t.co/NRHBwHLqSi https://t.co/nj8eaGiU50
Dr. John Cush RheumNow
3 years 5 months ago
Watch: Meetings should be like Oktoberfest
https://t.co/pZGOYXINir https://t.co/RIXmpRztaL
Dr. John Cush RheumNow
3 years 5 months ago
Watch: Modern Management of PsA Faculty Panel Q&A ,
https://t.co/WIESJSL8WF https://t.co/0k7FyYkFtc
Dr. John Cush RheumNow
3 years 5 months ago
Chinese study of 4091 SLE pts, 3% (106) dx w/ osteonecrosis (AVN). AVN risk factors included:
- SLE onset age ≤ 30 (HR 1.6)
- Arthritis (HR 1.6)
- Organ damage (HR 2.6)
- RNP+ (HR 1.7)
- High steroid doses (HR 1.7) https://t.co/DnqhEIWztY https://t.co/aP0uh0oh1x
Dr. John Cush RheumNow
3 years 5 months ago
Proposed AOSD criteria: 80 AOSD vs 60 autoimmune pts: \Nneed 7 points = AOSD dx (sensitivity 92%, specificity 93%, AUC 93%):
- typical rash 3 pts
- fever ≥ 39°C 3 pts
- pharyngitis 2 pts
- arthritis 2 pts
- glycosylated ferritin≤ 20% 1 pt https://t.co/iLUryBVa7C https://t.co/HTWgAucBIm
Dr. John Cush RheumNow
3 years 5 months ago
2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections
Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with AIIRD, that may be immunocompromised.
https://t.co/eAN3X3kAHV https://t.co/qpFc7hlG7u
Dr. John Cush RheumNow
3 years 5 months ago
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis
A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).
https://t.co/tYOwsNaiGy https://t.co/Bpfft4J9MB
Dr. John Cush RheumNow
3 years 5 months ago
Heart to Heart: Cardiovascular Risk in RA
Tune in as Dr. Christina Charles-Schoeman and Dr. Roy Fleischmann discuss how to help mitigate CVD risk in patients with RA in the latest therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/52g6cnI5Wi https://t.co/E87OUHWFib
Dr. John Cush RheumNow
3 years 5 months ago
Comprehensive full read review of Cutaneous Lupus Erythematosus - pathogenesis, pathology and treatment options. https://t.co/J7C0511kBJ https://t.co/ILhcpeT5cx
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
